Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial.

CONCLUSIONS: Low-dose metformin reprograms the TIME to an activated status and may be a suitable immune response modifier for further investigation in ESCC patients.
PMID: 32646922 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 8, 2020 Category: Cancer & Oncology Authors: Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, Yeung SJ, Bremer E, Zhang H Tags: Clin Cancer Res Source Type: research